- Citations, last 5 years
- 356.5k
- Works, last 5 years
- 25.4k
- h-index
- 1,797
- Scientists listed
- 655
- Grants since 2016
- 3 144
Grants received
2019–2026 · research · R35
Identification of Novel Oncogenic Signaling Pathways using Viral Perturbations
James A. Decaprio · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2024 · program · P01
Informed Combination Strategies for Peripheral T-cell Lymphomas
Birgit Knoechel · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2023 · career development · K00
Cancer Therapeutic Resistance: Implication of AcAPE1 Mediated DNA Repair and T-Cell Based Immunotherapy
Shrabasti Roychoudhury · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2024 · research · R01
Incomplete Penetrance via Edgetic Suppression
Michael A Calderwood · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2024 · career development · K08
Integration of early genetic alterations and inflammation in gastroesophageal premalignancy
Nilay Sethi · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2021 · research · R21
A statistical framework to systematically characterize cancer driver mutations in noncoding genomic regions
Eliezer M Van Allen · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2026 · research · R35
Targeting High-Risk Lymphoid Neoplasms
David Marc Weinstock · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2022 · fellowship · F32
Elucidating the role of SHOC2 to enhance MEK inhibitor sensitivity in pancreatic cancer
Jason Kwon · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2022 · fellowship · F32
Elucidating the role of SHOC2 to enhance MEK inhibitor sensitivity in pancreatic cancer
Jason Kwon · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019 · fellowship · Pew Biomedical Scholars Program
Philip Kranzusch — Pew Biomedical Scholar (2019)
Philip Kranzusch · Dana-Farber Cancer Institute · funded by Pew Charitable Trusts
2019–2024 · research · R01
Defining mechanisms of succinate regulation over adipose tissue thermogenesis
Edward Thomas Chouchani · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2024 · research · R01
Regulators of Cancer Immunotherapy Response
Myles A Brown · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2024 · research · R01
Defining mechanisms of succinate regulation over adipose tissue thermogenesis
Edward Thomas Chouchani · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2024 · research · R50
Functions of Cyclin/CDK complexes in development and cancer
Yan Geng · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2023 · research · R01
Defining mechanisms of succinate regulation over adipose tissue thermogenesis
Edward Thomas Chouchani · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2023 · research · R01
Interface-resolution domain-domain interactome map of the yeast complexome
Marc Vidal · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2024 · research · R01
CDK7 inhibitors as a new strategy to overcome treatment resistance in ER+ metastatic breast cancer
Rinath M. Jeselsohn · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2026 · research · R35
Identification of Novel Oncogenic Signaling Pathways using Viral Perturbations
James A. Decaprio · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2024 · research · R01
CDC7 kinase in normal and cancer cells: potential implications for cancer treatment
Peter Sicinski · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2023 · research · R01
Novel Screening Platform for Discovery of DUB Targeting Probes
Sara J Buhrlage · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2023 · research · R01
Interface-resolution domain-domain interactome map of the yeast complexome
Marc Vidal · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2024 · career development · K08
Understanding and addressing sub-optimal responses to CAR T cell therapy for Multiple Myeloma
Eric L Smith · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2024 · research · R01
Biomarker screening algorithms for the improved early detection of hepatocellular carcinoma
Nabihah Tayob · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2021 · career development · K99
Direct whole-genome haplotype-resolved assembly using sequence graphs
Shilpa Garg · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2024 · research · R01
CDK7 inhibitors as a new strategy to overcome treatment resistance in ER+ metastatic breast cancer
Rinath M. Jeselsohn · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2025 · career development · K08
The roles of anti-apoptotic proteins BCL-XL and MCL1 in mediating survival of high-grade serous ovarian cancer following drug-induced DNA damage
Elizabeth Harmon Stover · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019 · research · Essential Open Source Software for Science (EOSS)
Continuous Improvement to Essential High-Throughput Bio-Sequence Aligners
Heng Li · Dana-Farber Cancer Institute · funded by Chan Zuckerberg Initiative
2019–2026 · research · R35
Structure, mechanism, and pharmacology of BRAF and its partners in the RAS/RAF/MAP kinase pathway
Michael J Eck · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2024 · career development · K08
Integration of early genetic alterations and inflammation in gastroesophageal premalignancy
Nilay Sethi · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2025 · cooperative agreement · UG1
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care
Harold John Burstein · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2023 · research · R01
Regulators of Cancer Immunotherapy Response
Xiaole Shirley Liu · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2028 · research · R01
Development and vascularity of intestinal mesenchyme
Ramesh A Shivdasani · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2023 · research · R01
Interface-resolution domain-domain interactome map of the yeast complexome
Marc Vidal · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2021 · research · R21
Efficient methods for identifying cryptic relatedness in millions of individuals
Alexander Gusev · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2024 · career development · K08
Expectations for Pediatric Cancer Treatment (EXPECT): A Family-Centered Intervention to Prepare Parents for Pediatric Leukemia Therapy
Katie A. Greenzang · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2026 · research · R35
Reading mitochondrial apoptotic signaling to identify active cancer therapeutics
Anthony G Letai · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2024 · research · R01
Defining mechanisms of succinate regulation over adipose tissue thermogenesis
Edward Thomas Chouchani · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2021 · grant · PRCRP
Targeting the G2/M Checkpoint in Glioblastoma with a Combined Loss of TP53 and CDKN2A
Sangita Pal · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2019–2022 · career development · K99
Structure and Function of ATP-Dependent Chromatin Remodeling Complexes in Human Cancer
Nazar Mashtalir · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2024 · research · R01
The Function of CDK5 in Metastasis
Peter Sicinski · Dana-Farber Cancer Institute · funded by National Institutes of Health
